Logo
x

Search

Subscribe Now

non-muscle invasive bladder cancer

Merck & Co's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Merck & Co's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle I...

  • January 9, 2020
Photocure Partner Asieris Report the Completion of Patients Enrollment in P-III Clinical Trial of Hexvix in China

    Photocure Partner Asieris Report the Completion of Patients Enrollment in P-III Clinical Trial of Hexvix in China

    • July 6, 2023
    enGene to go Public via Forbion European Acquisition Corp. SPAC Merger for ~$135M

      enGene to go Public via Forbion European Acquisition Corp. SPAC Merger for ~$135M

      • May 18, 2023
      Ferring’s Adstiladrin (nadofaragene firadenovec-vncg) Receives the US FDA’s Approval for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

        Ferring’s Adstiladrin (nadofaragene firadenovec-vncg) Receives the US FDA’s Approval for BCG-Unresponsive Non-Muscle Invasive Blad...

        • December 16, 2022
        enGene Reports Preliminary Results of EG-70 in P-I/II (LEGEND) Trial for the Treatment of Non-Muscle Invasive Bladder Cancer

          enGene Reports Preliminary Results of EG-70 in P-I/II (LEGEND) Trial for the Treatment of Non-Muscle Invasive Bladder Cancer

          • February 10, 2022
          UroGen Initiates P-III (ENVISION) Study of UGN-102 for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

            UroGen Initiates P-III (ENVISION) Study of UGN-102 for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Ca...

            • February 4, 2022
            Merck & Co

              Merck & Co's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle I...

              • January 9, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.